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s much as one third of the adult population
reports difficulty sleeping
1-3 and the widespread use of
prescribed hypnotic medication,as well as nonprescrip-
tion remedies, is an indirect reflection of this high fre-
quency of sleep complaints.
2,4 Sleep disturbance is con-
sidered as the second most common symptom of mental
distress.
5 Individuals reporting disturbed sleep are more
likely to report emotional distress and recurrent health
problems.
1 In fact, disturbed sleep is a common finding
in psychiatric illnesses.Some patients will even attribute
their daytime psychiatric symptoms to abnormal sleep
and believe that improved sleep will solve their prob-
lems.In some cases,the psychological symptoms associ-
ated with a primary sleep disorder could indeed improve
with adequate therapy,for instance,the altered states of
consciousness or depression encountered in some
patients with sleep apnea could indeed improve with
nasal continuous positive airway pressure treatment.In
primary psychiatric disorders, the sleep complaint usu-
ally parallels the state of the disorder, and sleep
improves when the psychiatric symptoms improve.
Another point is that alterations of sleep by psychiatric
conditions are likely to have underlying brain neuro-
transmitter dysfunction directly involved in the patho-
physiological process of the disease. Indeed, neuro-
transmission disturbances,such as those encountered in
mental disorders,are reflected in spontaneous alteration
of sleep continuity and architecture.The corrective effect
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Brain neurotransmitter dysfunctions involved in the
pathophysiological processes of psychiatric disorders are
likely to be reflected by concomitant alterations in sleep
continuity and architecture. Since the corrective effects of
psychotropic drugs on dysfunctional neurotransmission
systems can be evidenced through polysomnographic
recordings, one may consider sleep as a kind of “window”
on the neurobiology of psychiatric disorders. During the
last 10 years, major breakthroughs in our understanding
of sleep-wake mechanisms have provided some indica-
tions on how psychotropic drugs could influence the
sleep-wake cycle. In this review, recent inroads into the
understanding of sleep regulatory neural mechanisms are
introduced and discussed in terms of the effects of psy-
chotropic drugs. The relationship between the patho-
physiological process of a disease, its consequence on
sleep, and the corrective effect of a psychotropic drug are
exemplified by two psychopathological states: substance
withdrawal and major depression. One may conclude that
polysomnographic recordings are a unique noninvasive
tool to analyze brain functioning, and are particularly well
suited to evaluating the objective effects of new psy-
chotropic drugs.   
© 2005, LLS SAS Dialogues Clin Neurosci. 2005;7:323-334.on dysfunctional neurotransmission systems of psy-
chotropic drugs, such as antidepressants, is also evi-
denced through polysomnographic recordings.Sleep can
thus be considered as a kind of window on the neurobi-
ology of psychiatric disorders.The first section of this
review will introduce recent inroads into understanding
sleep-regulatory neural mechanisms.The following sec-
tions deal with the way psychotropic drugs interact with
mechanisms involved in sleep-wake regulation. Finally,
the relationship between the pathophysiological process
of a disease,its consequence on sleep,and the corrective
effect of a psychotropic drug will be exemplified.
Sleep basics
Electrophysiological recordings of human brain reveal
three distinct state of existence:wakefulness,rapid eye
movement (REM) sleep,and non-REM (NREM) sleep.
The distinction between sleep and wakefulness is attrib-
uted to the synchronization and desynchronization of
thalamocortical circuits.
6,7Wake-like or “desynchronized”
(low-amplitude and high-frequency) electroencephalo-
graphic (EEG) activity with clusters of REM and very
low levels of muscle tone characterize REM sleep.
NREM sleep includes all sleep except REM sleep,and is
by convention divided into four stages corresponding to
increased depth of sleep as indicated by the progressive
dominance of “synchronized”EEG activity (also known
as low-voltage high-amplitude delta or slow-wave activ-
ity);in this respect,sleep stages 3 and 4 are collectively
labelled as delta sleep or slow-wave sleep (SWS).
Recurrent cycles of NREM and REM sleep of about 90
min characterize normal human sleep.In the successive
cycles of the night, the duration of stages 3 and 4
decrease, and the proportion of the cycle occupied by
REM sleep tends to increase.The REM episodes occur-
ring late in the night have more eye movement bursts
than REM episodes occurring early in the night.
8
Sleep-wake alternation is classically viewed as resulting
from the interaction of two regulating processes (circa-
dian–C and homeostatic–S).
9The propensity to sleep or
be awake at any given time is a consequence of a sleep
debt (process S) and its interaction with wake-promot-
ing signals coming from the circadian clock (process C)
located in the suprachiasmatic nucleus (SCN). This
wake-promoting signal opposes the sleep need, which
progressively increases from morning awakening,ensur-
ing an even degree of alertness throughout the day.
10At
sleep onset, an imbalance between the two opposing
influences favor sleep-promoting signals, and the sleep
need and its electrophysiological signature, slow-wave
activity, is at its highest level.Throughout sleep and up
to final morning awakening, there is a progressive
decline in slow-wave activity reflected by an increase in
REM sleep proportion across successive REM/NREM
cycles. During the last decade, research lent support to
the idea that three interacting neuronal systems (a wake-
promoting system, an NREM-promoting system, and a
REM-promoting system) are involved in this complex
regulation construct.
Different structures sending widespread cortical projec-
tion and located in the brain stem, the hypothalamus,
and the basal forebrain constitute the wake-promoting
or arousal system (Figure 1).
11,12 Glutamatergic brain
stem reticular neurons,cholinergic neurons of the basal
forebrain, and monoaminergic transmission are largely
implicated in the arousal system.
13 It has been shown
that serotonergic (dorsal raphe nuclei [DRN]), nora-
drenergic (locus ceruleus [LC]) and histaminergic
(tuberomammillary nucleus [TMN]) activity is high dur-
ing wakefulness, decreases during NREM stages, and
becomes almost silent during REM sleep.
14 The role of
the dopaminergic system is less well established; how-
ever,recent studies indicated that lesions of wake-active
dopaminergic cells in the ventral periaqueductal gray
reduce waking
15 and that dopamine D1,D 2, and D3
receptor agonists increase waking and reduce REM and
NREM sleep.
16-18 Orexin (also known as hypocretin)
neurons located in the perifornical region of the lateral
hypothalamus seem to play a particularly important role
in arousal since they project not only over the entire iso-
cortex, but also to additional arousal systems, including
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Selected abbreviations and acronyms
DRN dorsal raphe nucleus
GABA γ-aminobutyric acid
LC locus ceruleus
LDT laterodorsal tegmental (nucleus)
NP nicotine patch
NREM non–rapid eye movement
PPT pediculopontine tegmental (nucleus)
REM rapid eye movement
SCN  suprachiasmatic nucleus
SWS slow-wave sleep
TMN tuberomammillary nucleus
VLPO ventrolateral preoptic nucleusthe aforementioned monoaminergic and cholinergic sys-
tems.
19,20 The role of orexin in arousal regulation is fur-
ther exemplified with narcolepsy,a sleep disorder char-
acterized by excessive daytime sleepiness and deficiency
of the orexin system.
21-23
An NREM-promoting system has been evidenced in the
hypothalamus (Figure 2).Electrophysiological recordings
have identified GABAergic (GABA, γ-aminobutyric
acid) SWS-active neurons in a specific area,the ventro-
lateral preoptic nucleus (VLPO),where lesions produce
insomnia in animals and humans.
24These cells also con-
tain galanin and project to all monoaminergic systems,
inhibiting activity during NREM sleep,and receive inputs
from multiple brain systems that regulate arousal and
autonomic and circadian functions.
25 Recent research
implicates adenosine in the homeostatic regulation of
Sleep disturbances,psychiatric disorders,and psychotropic drugs - Staner Dialogues in Clinical Neuroscience - Vol 7 . No.4 . 2005
325
Figure 1. Simplified representation of the various structures implicated
in arousal mechanisms and their interrelationships. Light-blue
boxes, activated structures; blue boxes, deactivated structures;
light-blue arrows, excitatory influences; blue arrows, inhibitory
influences. GABA, γ-aminobutyric acid; PPT/LDT pediculo-
pontine tegmental/laterodorsal tegmental nuclei; TMN,
tuberomammillary nucleus; VLPO, ventrolateral preoptic
nucleus. 
Reproduced from reference 12: Staner L, Luthringer R, Macher JP.
Développement de molécules actives dans l’insomnie : actualités et
aspects methodologiques. Rev Neurol (Paris). 2003;159(11 suppl):6S48-
6S55. Copyright © 2003. Masson, Paris, France.
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Figure 2. Simplified representation of various structures implicated in
non–rapid eye movement (NREM) mechanisms and their inter-
relationships. Light-blue boxes, activated structures; blue
boxes, deactivated structures; light-blue arrows, excitatory
influences; blue arrows, inhibitory influences. GABA, 
γ-aminobutyric acid; PPT/LDT pediculopontine tegmental/lat-
erodorsal tegmental nuclei; TMN, tuberomammillary nucleus;
VLPO, ventrolateral preoptic nucleus.
Reproduced from reference 12: Staner L, Luthringer R, Macher JP.
Développement de molécules actives dans l’insomnie : actualités et
aspects methodologiques. Rev Neurol (Paris). 2003;159(11 suppl):6S48-
6S55. Copyright © 2003. Masson, Paris, France.
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Orexinsleep via actions on the VLPO and other sleep regulatory
regions such as the basal forebrain.
26Adenosine functions
as a natural sleep-promoting agent,accumulating during
period of sustained wakefulness and decreasing during
sleep;it has been shown to promote SWS through direct
inhibitory effects on cholinergic neurons of the basal
forebrain
26 and have indirect stimulatory effects on the
VLPO.
27,28A further inhibition of wake-promoting mech-
anism could occur through orexinergic neurons,since a
study identified Gi protein–coupled adenosine A1 recep-
tors on this group of neurons.
29
Regarding the circadian influence on the sleep-wake
rhythm,recent studies suggested that the SCN regulates
sleep-wake mechanisms through the dorsomedial hypo-
thalamus,a key output nucleus of the SCN that inhibits
VLPO and stimulates orexin-containing neurons in the
lateral hypothalamus.
30,31 Melatonin,the hormone of the
pineal gland secreted at night and concerned with bio-
logical timing, could mediate its sleep-inducing effect
through inhibitory influence on SCN neurons
32 and
cholinergic neurons of the basal forebrain.
33
The REM-promoting system comprises “REM-on”
cholinergic neurons located in the laterodorsal tegmen-
tal (LDT) and pediculopontine tegmental (PPT) nuclei
(Figure 3).The McCarley and Hobson reciprocal inter-
action model,first proposed in 1975,and regularly revis-
ited,
14 posits a bidirectional inhibitory influence between
these REM-on neurons and both the serotonergic DRN
and the noradrenergic LC, called “REM-off” neurons.
Transition from NREM to REM occurs when activity in
the aminergic REM-off neurons ceases. Cholinergic
LDT/PPT REM-on neurons are then involved in the ini-
tiation of cortical desynchronization through excitatory
inputs to the thalamus and in the occurrence of muscle
atonia and REMs. During REM sleep, the excitatory
input from the REM-on neurons to the DRN and LC
leads to a gradual increase in the activity of the REM-
off neurons,which in turn inhibit REM-on neurons until
the REM episode ends. GABAergic and glutamatergic
modulations of this aminergic-cholinergic interplay have
been proposed in the revised version of the model.
14
The effects of drugs on wake- and 
sleep-inducing mechanisms
In the following sections, we will review the effects of
psychotropic drugs on the three interacting neuronal
systems that have been proposed to play a key role in
sleep-wake regulation (the wake-promoting system,the
NREM-promoting system,and the REM-promoting sys-
tem).The first four sections deal with drugs acting on
wake- or NREM sleep–promoting neurons, while the
following section concerns drugs acting on the REM-
promoting system with special reference to antidepres-
sant drugs.Whether drugs induce wakefulness (“waking
drugs”) or sleep (“hypnosedative drugs”) depend on
their liability to stimulate or inhibit wake- or NREM
sleep–promoting neurons.Before going further,it should
be stressed that the net effects of a hypnosedative drug
inhibiting wake-promoting neurons will be very similar
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Figure 3. Simplified representation of various structures implicated in rapid
eye movement (REM) mechanisms and their interrelationships.
Light-blue boxes, activated structures; blue boxes, deactivated
structures; light-blue arrows, excitatory influences; blue arrows,
inhibitory influences. GABA, γ-aminobutyric acid; PPT/LDT
pediculopontine tegmental/laterodorsal tegmental nuclei; TMN,
tuberomammillary nucleus; VLPO, ventrolateral preoptic nucleus.
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Orexinto the effects of a drug stimulating NREM-promoting
neurons. The converse is true for waking drugs: the
effects of a drug inhibiting NREM-promoting neurons
will parallel those induced by a drug stimulating wake-
promoting neurons.Finally,it should be recognized that
a distinction between drugs acting on wake- or NREM-
promoting neurons is somewhat arbitrary, due to the
close reciprocal negative feedback existing between
these two groups of neurons.
7
Some drugs directly influence both wake-promoting
neurons and sleep-promoting neurons, but in an oppo-
site way; this is the case for compounds influencing
adenosine transmission such as caffeine. Caffeine is a
psychoactive substance enhancing vigilance perfor-
mance on psychomotor tasks and significantly affecting
sleep at a dose of more than 100 to 150 mg.
34,35 It is now
widely accepted that the vigilance mechanism of caffeine
acts via the antagonism of adenosine receptors. The
physiology of the adenosinergic transmission has been
recently reviewed,
36 as well as its implication in sleep-
wake mechanisms.
26 Adenosine, formed by breakdown
of adenosine triphosphate (ATP),is present both intra-
and extracellularly, and the balance is maintained by
membrane transporters, but when energy expenditure
exceeds energy production,adenosine levels increase in
the extracellular space. In humans, adenosine exerts
most of its effects through activation of two high-affin-
ity receptors (the A1 coupled to “inhibitory”Gi proteins
and the A2A coupled to “stimulatory” Gs protein).A1
receptors are involved in the inhibitory effect of adeno-
sine on the wake-active cholinergic neurons of the basal
forebrain, while there are some indications that A2A
receptors could influence the dopaminergic control of
wake-promoting mechanisms.
37Adenosine may also dis-
inhibit sleep-active VLPO neurons by removing
GABAergic inhibitory inputs, possibly via A1 recep-
tors.
27,28The caffeine-induced increase in vigilance level
results from the blockade of A1 and A2A receptors.
Accordingly, it is thought that caffeine exerts its effects
through two complementary mechanisms: inhibition of
wake-promoting cholinergic and dopaminergic influence
and disinhibition of sleep-promoting neurons of the
VLPO.
It thus emerges that there is a potential role of adeno-
sine A1 and A2A receptor antagonists as arousal stimu-
lators and agonists as sleep promoters.Preclinical stud-
ies with such compounds have reported promising
results,
26 but no clinical trials have been published to
date. Since direct adenosine agonists may have marked
side effects such as hypotension and bradycardia,
36 the
use of substances that indirectly modulate the level of
endogenous adenosine, such as adenosine uptake
inhibitor
38 or adenosine kinase inhibitor,
39 may be prefer-
able to the use of direct adenosine agonists.
Drugs enhancing the activity of 
wake-promoting neurons
Amphetamine-like drugs and modafinil are the two most
popular wake-promoting medications used for the treat-
ment of narcolepsy,a sleep disorder characterized by exces-
sive daytime sleepiness.Amphetamine,methylphenidate,
and cocaine are known to act pharmacologically by block-
ing the reuptake and enhancing the release of noradrena-
line,dopamine,and serotonin within the synaptic cleft of
monoamine synapses.
40 The exact mechanism by which
amphetamine-like stimulants induce their wake-promot-
ing effects remains to be elucidated,but there is growing
evidence that the dopaminergic system is mostly impli-
cated.
41 For instance,it has recently been demonstrated that
dopamine transporter knockout mice were totally insensi-
tive to the wake-promoting properties of classical stimu-
lants suggesting that amphetamine-like compounds require
the dopamine transporter for their wake-promoting
effects.
42
Despite numerous reports of its neuropharmacological
action on the central nervous system (CNS),the wake-pro-
moting mechanism of action of modafinil remains uncer-
tain. Using c-Fos immunochemistry in cats, it has been
shown that amphetamine-like drugs do not share with
modafinil the same pattern of c-Fos activation in the brain.
Amphetamine and methylphenidate activate neurons
mainly in the cortex and the striatum,whereas modafinil-
induced wakefulness was mainly associated with activated
neurons in the hypothalamus.
43,44Another study involving
c-Fos labelling highlighted Fos activation mainly in the
TMN and in orexin-containing neurons of the perifornical
nucleus.
45This suggests that modafinil induces wakefulness
by mechanisms distinct from amphetamine-like drugs.It
has been suggested that modafinil-induced arousal could
be related to noradrenergic transmission,since modafinil
affects the firing of the LC
46 and its arousal effects are
blocked by α1 and βadrenergic receptor antagonists.
47 One
study shows that modafinil increases noradrenergic release
in the hypothalamus,but also both dopaminergic and sero-
tonergic transmission in the cortex, suggesting that the
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327effects of modafinil are not entirely mediated through
noradrenergic transmission.
48
Besides amphetamine-like drugs and modafinil,the devel-
opment of drugs acting through the histaminergic or orex-
inergic system is an area of active research in the field of
new therapeutic approach for the treatment of major
sleep-wake disorders,such as hypersomnia and narcolepsy.
H3 receptors are an important target for arousal control
and treatment of excessive daytime somnolence,since they
are both autoreceptors controlling histamine-containing
neuron activity and heteroreceptors, modulating the
release of other neurotransmitters including acetylcholine,
dopamine,and noradrenaline in brain regions that are cru-
cial for the maintenance of wakefulness.
49,50Administration
of H3 receptor antagonists and inverse agonists induced a
total suppression of slow-wave activity and spindles and a
marked enhancement of fast rhythm,thus eliciting waking
and increasing vigilance.
51,52 Moreover,recent studies have
shown that H3 receptor blockade enhances cognition in
rats.
53These studies suggest that the potential benefit of H3
receptor antagonists and inverse agonists are not limited
to promoting wakefulness because they could also
improve general level of vigilance and cognitive responses
in nonsomnolent individuals.
50 However,no clinical trials
have yet been published showing that H3 receptor block-
ade promotes wakefulness in humans.
The pharmacology of the orexin system is,up to now,also
limited to animal data.Orexins are a pair of neuropeptides,
orexin-A and orexin-B,derived from a common precursor
peptide,whose actions are mediated by two G protein–cou-
pled receptors termed orexin receptor type 1 (OX1R) and
orexin receptor type 2 (OX2R).
54 Both receptors are
expressed in serotonergic neurons of the DRN,cholinergic
neurons of the LDT/PPT, and the hypothalamus, while
OX1R is specific to the noradrenergic neurons of the LC
and OX2R to histaminergic neurons of the TMN.
55,56
Considering that canine narcolepsy results from a mutation
of the OX2R gene
57 and the phenotypic differences
between OX1R and OX2R knockout mice,there are some
indications that the lack of an orexin signal via OX2R con-
tributes to the pathogenesis of narcolepsy.
58 Since orexin is
below detectable limits in the cerebrospinal fluid of human
narcolepsy patients,
21,22 whose brains exhibit a nearly com-
plete loss of neurons expressing orexin
22,23 an orexin agonist
should be able to compensate for orexin deficiency, and
therefore should be efficient in promoting wakefulness.
However,no available clinical data so far support the effec-
tiveness of this approach in treating sleep disorders.
Sleep-inducing drugs that impair the activity 
of wake-promoting neurons
Many psychotropic drugs, known as sedatives, interfere
with wake propensity mechanisms.Indeed,drugs inhibit-
ing cholinergic, noradrenergic, dopaminergic, seroton-
ergic, or histaminergic neurotransmission have shown
various sedative effects. Potent sedative drugs used in
psychiatry to treat psychomotor agitation, such as phe-
nothiazine derivatives,often antagonize several of these
systems.Antagonizing only one of these alerting systems,
such as the histaminergic system with first-generation
histamine H1 antagonists used for the treatment of aller-
gies, procures merely mild-to-moderate sedation.
However, as stated in the previous section, a renewed
interest in histaminergic function,and more specifically
in histamine H3 receptors, has grown during the last
decade. Thus, H3 receptor agonists should lower 
histamine release in neuronal terminals as well as the
release of other wake-promoting neurotransmitters,
such as acetylcholine, dopamine, and nor-adrenaline.
Preliminary results indicate that H3 agonists increase
SWS in animals
59,60 and it can thus be expected that clin-
ically suitable agonists will improve sleep in some types
of insomnia.
In the same way,and according to the key involvement
of the orexin system in the orchestration of arousal (see
above), orexin antagonists could be potential sleep-
inducing drugs.Moreover,some studies have suggested
that the orexin neurotransmission may be associated with
the high-arousal stress-like states
61,62 that typically char-
acterize insomniac patients.Indeed,patients having com-
plaints of insomnia show electrophysiological and psy-
chomotor evidence of increased daytime arousal
63-66 as
well as indications of other stress-related reactions such
as increased hypothalamic-pituitary-adrenal axis (HPA)
activity,
67 and increased sympathetic tone.
68 In a first
attempt to record in vivo the activity of orexin neurons,
Mileykovskiy et al
69 showed that,as expected,orexin neu-
rons displayed very low discharge levels in both REM
and NREM sleep,but that discharge rates were not sig-
nificantly elevated during quiet waking,suggesting that
orexin neurotransmission is not associated with waking
per se.In contrast,high discharge rates were observed in
active and/or alert waking. This further supports the
potential clinical value of drugs antagonizing the orexin
system in the treatment of stress-related sleep disorders,
such as insomnia.
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treatment of sleep disturbances 
in nicotine and alcohol withdrawal
Sleep disturbances following substance withdrawal,such
as nicotine or alcohol, reflect complex hyperarousal
states involving stress-related disturbances due to the
craving phenomenon and peculiar substance-induced
neurotransmission imbalance.For instance,polysomno-
graphic recordings performed during the week follow-
ing nicotine withdrawal in heavy cigarette smokers have
shown increased sleep disruption.
70,71 It should,however,
be stressed that even before withdrawal, current smok-
ers subjectively complain of decreased sleep time and
a fragmented sleep,mostly during the second part of the
night.
71-74 These observations probably relate to the
tobacco withdrawal state occurring each night in heavy
smokers rather than to nicotine itself.Indeed,the cholin-
ergic system is a major constituent of the wake-promot-
ing system and it contributes to cortical arousal through
its ascending components.
13The involvement of nicotine
acetylcholine receptors in these cholinergic effects is
suggested by studies showing that nicotine injections
increase waking,
75 and that mice lacking the β2 subunit
gene of the nicotine acetylcholine receptor,a major com-
ponent of high affinity nicotine-binding sites in the
brain, exhibited a reduced fragmentation of NREM
sleep through microarousals.
76 It is also worth noting that
24-h transdermal nicotine delivery system (nicotine
patch [NP]),when administered in nonsmoking healthy
volunteers has a sleep-disrupting effect.
77,78 However,
during tobacco withdrawal, 24-h NP induced an
improvement of sleep fragmentation and an increase in
the proportion of SWS in cigarette smokers,thus reflect-
ing the fact that nighttime nicotine administration
decreases rather than increases arousal level in cigarette
smokers.
71 This was further demonstrated by a study
comparing a 16-h NP (applied only when awake) with a
24-h NP (applied continuously); the results show that
microarousals were significantly more decreased by the
24-h NP compared with the 16-h NP, and only the for-
mer was found to increase SWS, suggesting a more
potent protective effect of the 24-h NP on the tobacco-
withdrawal–induced sleep fragmentation.
79The sleep dis-
turbances encountered with the 16-h NP were probably
related to an insufficiently compensated withdrawal
state (nicotine level is too low to balance tobacco with-
drawal).
Postdetoxification sleep disturbances in alcohol depen-
dence may reflect the alcohol-induced alterations of a
number of neurochemical systems that are believed to reg-
ulate sleep.
80 Acute alcohol intake decreases neuronal
excitability through its potentiation of inhibitory
GABAergic mechanisms and its attenuation of excitatory
glutamatergic mechanisms.
80-82 Over time, with chronic
alcohol use,these neurotransmitter systems adapt,in order
to maintain homeostasis and optimize brain functioning,
and tolerance develops.However,with discontinuation of
alcohol,a withdrawal-associated neural hyperexcitability
occurs,favoring arousal and thus interfering with sleep-
regulating mechanisms in addition to other negative symp-
toms.
80-82 Although the most commonly used strategy to
renormalize neuronal excitability is to increase
GABAergic transmission,influencing glutamatergic trans-
mission could also reduce postwithdrawal neuronal hyper-
excitability.Research on alcoholism has recently focused
on the glutamatergic system as preclinical studies
83,84 and
human laboratory studies,
82 provided compelling evidence
for a role of the glutamate system in alcohol dependence.
Moreover,drugs targeting the glutamatergic systems such
as acamprosate are emerging as novel pharmacothera-
peutic options for treating alcohol dependence.
85-87 Indeed,
a magnetic resonance imaging study showed that acam-
prosate lowers glutamatergic neurotransmission in human
subjects.
88 In a polysomnographic study,it was found that
acamprosate treatment,initiated 1 week before alcohol
withdrawal in alcohol-dependent subjects,enhanced sleep
continuity during acute and protracted alcohol withdrawal
by increasing time spent in sleep stage 3 and decreasing
wakefulness after sleep onset (Staner L et al,unpublished
data), while it prolonged REM sleep latency. Studies in
healthy subjects have shown that acamprosate is devoid of
any sedative effects per se.
89Thus,the present results bring
support to the idea that lowering the glutamate-related
hyperarousal could influence postwithdrawal sleep dis-
turbances.In accordance with this,in the same group of
patients,daytime assessments by EEG and magnetoen-
cephalography also indicate that acamprosate attenuates
electrophysiological signs of CNS hyperexcitability.
90
Sleep-inducing drugs that enhance the 
activity of NREM sleep–promoting neurons
The most prescribed hypnotic drugs, benzodiazepines
and benzodiazepine-related drugs such as zolpidem and
zaleplon, have been shown to allosterically and posi-
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329tively modulate the action of GABA via direct interac-
tion with their recognition sites, ie, by increasing the
affinity of GABA for its own GABAA sites. GABAA
receptors are formed by the assembly of five protein
subunits among the 18 subunits that have been identi-
fied by cloning techniques: α (6 isoforms, α1 to α6),
β (3 isoforms, β1 to β3), γ (3 isoforms, γ1 to γ3), ρ (3 iso-
forms,ρ1 to ρ3),δ (1 isoform),ε (1 isoform),and θ (1 iso-
form).
91 However,most GABAA receptors are believed
to be composed of two α, one β, and two γ subunits.
Receptors containing the α1, α2, α3, or α5 subunits in
combination with any of the β subunit and the γ2 are
most prevalent in the brain, the α1β2γ2 being the most
prevalent subunit combination (60% of all GABAA
receptors). Zolpidem and zaleplon are distinguished
from classical benzodiazepine by binding selectively to
GABAA receptors containing the α1 subunit,a subtype
of GABAA receptors thought to mediate sedative,anti-
convulsive,and amnesic effects of benzodiazepine drugs,
whereas α2-containing GABAA receptors relate to anx-
iolytic and myorelaxant effects.
91 Different mechanisms
could explain the hypnosedative effects of drugs enhanc-
ing GABAA neurotransmission. Firstly, GABA is the
major inhibitory neurotransmitter system in the mam-
malian CNS, and GABAA receptors are ubiquitous in
the CNS. Secondly, in the thalamus, these drugs could
reinforce the inhibitory influence of GABAergic neu-
rons of the reticular nucleus on the relay nuclei, which
are the crossing points of all sensorimotor afferents
going to the cortex. The reinforcement of inhibitory
influence on relay nuclei has been proposed to underlie
the decrease of high-amplitude delta slow-wave activity
and the concomitant increase in sigma spindling activity
during NREM sleep induced by drugs enhancing
GABAA neurotransmission.
92Thirdly,since VLPO sleep-
promoting neurons are GABAergic, drugs enhancing
GABAA neurotransmission will reinforce the VLPO
inhibitory effects on all wake-promoting structures.
Recent studies in a point-mutated mouse model have
suggested that effects of benzodiazepines on sleep-onset
latency and NREM sleep microstructure are mediated
through different subtypes of GABAA receptors.
Indeed,α2-containing GABAA receptors could relate to
the reduction of NREM delta activity,while α1-contain-
ing GABAA receptors could be implicated in the short-
ening of sleep-onset latency induced by benzodi-
azepines.
93-95 Consequently,it may be suggested that sleep
could be used a useful tool for the appraisal of α1
GABAA-mediated sedative versus α2 GABAA-medi-
ated anxiolytic properties of a benzodiazepine drug.
Other compounds enhancing GABAergic transmission
could be valuable hypnotic drugs,some of which are cur-
rently in development.The drugs in question are another
α1-containing GABAA-enhancing drug (indiplon),
GABA analogues such as gabapentin, a GABA reup-
take inhibitor (tiagabine), and a GABAA agonist
(gaboxadol).
96 These agents, except gaboxadol, non-
specifically enhance GABAergic transmission through
GABAA, GABAB, and GABAC receptors. It should be
stressed that the hypnotic effects of GABAB and
GABAC ligands are not qualitatively similar to those
obtained with GABAA ligands.
97
Major depression, REM sleep, 
and antidepressant drugs
More than 90% of depressed patients complain about
difficulties in falling asleep, sleep disruption, or early-
morning awakenings.
98Well-established sleep EEG find-
ings are disturbed sleep continuity (lengthening of sleep
latency and increased wake after sleep onset resulting in
decreased time spent asleep), deficit of SWS, especially
during the first sleep cycle,and REM sleep disinhibition.
The latter, also known as “increased REM sleep pres-
sure,” is described as a greater amount of REM sleep,
mostly in the beginning of the night (also reflected by
a shortened REM onset latency) and as an increase in
the actual number of REMs during this sleep stage
(REM density).
99,100 Many studies have suggested that
the REM sleep disinhibition profile is not pathogno-
monic for major depression, but provides evidence of
antidepressant-responsive conditions. Thus, beyond
depression, shortened REM sleep latencies have been
more reliably reported in conditions for which antide-
pressant drugs are recognized as effective,such as obses-
sive-compulsive disorder,
101 panic disorder,
102 generalized
anxiety disorder,
103 or borderline personality disorder.
104
Polysomnographic recordings in some patients with
anorexia nervosa
105 and alcohol dependence
106 could also
demonstrate a shortened REM latency,but a depressive
comorbidity was clearly present.
In 1982, McCarley posited that an imbalance between
aminergic and cholinergic influences underlie REM sleep
disinhibition in depressive disorder.
107 Conventional sup-
ports for the imbalance theory are based on the fact that
the REM sleep suppressant effect of antidepressant
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gic and/or serotonergic function or cholinergic blockade.
In some cases,as with most tricyclic antidepressants,all
three mechanisms may be involved. Antidepressant
drugs devoid of clear-cut REM-suppressant effects (ie,
bupropion, mirtazapine, nefazodone, tianeptine, tra-
zodone,and trimipramine) share one characteristic:their
potency to inhibit noradrenergic or serotonergic uptake
is absent,doubtful,or moderate.
108
There are several other arguments in favor of the 
aminergic/cholinergic imbalance theory. A recent
[
18F]deoxyglucose positron emission tomography (FDG-
PET) study by Nofzinger et al
109 of waking to REM sleep
changes reported that, compared with healthy subjects,
depressed patients showed increased activation of the
brain stem reticular formation limbic and anterior paral-
imbic cortex,and the executive cortex during REM sleep.
The authors suggested that their findings could reflect the
disinhibition of the REM-on cholinergic neurons either
directly (brain stem activation) or indirectly (through cor-
tical projections). Other evidence comes from studies
administering different cholinergic-enhancing drugs
(physostigmine, arecoline, RS86) in depressed patients.
These compounds induced,to various degrees,stronger
signs of REM sleep disinhibition than in healthy controls,
as well as,for some of them,an increased rate of awaken-
ings and arousals.
110 Other convincing arguments come
from the monoamine depletion paradigms.α-Methyl-para-
tyrosine,which inhibits catecholamine synthesis,provoked
REM sleep abnormalities in humans.
111 Rapid tryptophan
depletion induced by a tryptophan-free drink also disin-
hibited REM sleep without changing mood in individuals
recovered from depression.
112-115 Bhatti et al
116 extended
these observations to healthy volunteers (in these subjects,
a tryptophan-free drink decreased REM latency,increased
REM expressed as percentage of total sleep time, and
increased REM density),findings that were only partially
replicated by Voderholzer et al.
117
Conclusion
Polysomnographic recordings constitute a unique nonin-
vasive tool to analyze brain function.Neurotransmission
disturbances,such as those encountered in mental disor-
ders, are reflected in alterations of sleep continuity and
architecture.If we assume a neurobiological link between
sleep and these disorders, the recent explosion of basic
findings on the functional neuroanatomy of sleep-wake
regulation and the cellular basis of the various sleep
rhythms should raise new issues about our understanding
of psychiatric disorders.Sleep laboratory investigations are
a useful aid for the development of new psychotropic
drugs,since their influence on a particular neurotransmis-
sion system could be reflected in the polysomnographic
profile they induce.Moreover,this profile can be compared
with the polysomnographic profiles of reference drugs. ❏
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Alteraciones del sueño, trastornos psiquiá-
tricos y psicofármacos
Es probable que las disfunciones de la neurotrans-
misión cerebral involucradas en los procesos fisio-
patológicos de los trastornos psiquiátricos se refle-
jen en alteraciones concomitantes de la continuidad
y arquitectura del sueño. Ya que los efectos correc-
tores de los psicofármacos en los sistemas de neu-
rotransmisión disfuncionales pueden ser evidencia-
dos a través de registros polisomnográficos, es
posible considerar al sueño como un tipo de “ven-
tana” hacia la neurobiología de los trastornos psi-
quiátricos. Durante los últimos diez años los princi-
pales progresos en nuestra comprensión de los
mecanismos del sueño-vigilia han originado algu-
nas sugerencias acerca de cómo los psicofármacos
podrían afectar el ciclo sueño-vigilia. En esta revi-
sión se presentan y discuten avances recientes en la
comprensión de los mecanismos neurales regula-
dores del sueño a partir de los efectos de los psico-
fármacos. La relación entre los procesos fisiopato-
lógicos de una enfermedad, su consecuencia en el
sueño y los efectos correctores de un psicofármaco
se ejemplifican en dos estados psicopatológicos: la
privación de sustancias y la depresión mayor. Se
puede concluir que los registros polisomnográficos
constituyen una herramienta no invasora original
para analizar el funcionamiento cerebral y son
especialmente adecuados para evaluar los efectos
objetivos de nuevos psicofármacos.
Perturbations du sommeil, troubles
psychiatriques, et psychotropes
Les dysfonctionnements de la neurotransmission
impliqués dans la physiopathologie des troubles
psychiatriques se reflètent très probablement dans
les altérations concomitantes de la continuité et de
l'architecture du sommeil. Comme les médicaments
psychotropes corrigent les dysfonctionnements des
systèmes de neurotransmission, leurs effets peuvent
être mis en évidence par des enregistrements poly-
somnographiques. Le sommeil peut donc être consi-
déré, en quelque sorte, comme un reflet de la neu-
robiologie des troubles psychiatriques. Au cours des
10 dernières années, des avancées majeures dans
nos connaissances sur les mécanismes veille-sommeil
ont permis d'apporter quelques éléments d'expli-
cation sur la manière dont les médicaments psy-
chotropes pouvaient influer sur le cycle veille-som-
meil. Dans cette revue de la littérature, les
découvertes récentes dans notre compréhension
des mécanismes neuronaux impliqués dans la régu-
lation du sommeil sont présentées et discutées en
fonction des effets des médicaments psychotropes.
Les relations entre le processus physiopathologique
d'une maladie, ses conséquences sur le sommeil et
les effets correcteurs d'un médicament psychotrope
sont illustrés par deux exemples : le sevrage d’une
substance et la dépression majeure. En conclusion,
retenons que les enregistrements polysomnogra-
phiques représentent un outil unique, non invasif,
permettant d'analyser le fonctionnement cérébral
et particulièrement bien adapté pour l'évaluation
des effets objectifs d'un nouveau médicament psy-
chotrope.
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